Viking Therapeutics Shares Surge 13% in Pre-Market Trade

Viking Therapeutics Shares Surge 13% in Pre-Market Trade

Shares of Viking Therapeutics (VKTX) rose 12% in pre-market trading after the company said a study of VK2809 in an in vivo model of non-alcoholic steatohepatitis (NASH) demonstrated improvements across several key measures relevant to the development and progression of the disease. Animals receiving VK2809 experienced statistically significant improvements in non-alcoholic fatty liver disease activity score (NAS), liver collagen content, and liver fibrosis relative to vehicle-treated controls. NASH is a […]

Read More ˃